Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

v3.20.4
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Schedule of Other Current Assets

Other current assets consisted of the following as of September 30, 2020 and December 31, 2019:

 

    September 30, 2020     December 31, 2019  
    (unaudited)        
Lab supply inventory     2,423       1,825  
Prepaid expenses     489       971  
Funds in escrow     -       888  
Letter of credit     350       -  
Due from CGI     525       92  
Other     74       75  
Total other current assets   $ 3,861     $ 3,851  
Schedule of Basic and Diluted Net Loss Per Share

A reconciliation of the number of shares of common stock, par value $0.01 per share, used in the calculation of basic and diluted loss per share for the three- and nine-month periods ended September 30, 2020 and 2019 is as follows:

 

    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2020     2019     2020     2019  
    (unaudited)     (unaudited)  
Basic weighted average number of common shares     4,038       3,820       4,025       3,717  
Potential dilutive effect of stock-based awards     -       -       -       -  
Diluted weighted average number of common shares     4,038       3,820       4,025       3,717  
Schedule of Computation of Dilutive Securities

The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 shares for the three- and nine-months ended September 30, 2020, and the following outstanding stock-based awards and warrants, were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands):

 

    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2020     2019     2020     2019  
    (unaudited)     (unaudited)  
Options     878       394       878       394  
Stock-settled stock appreciation rights (SARs)     -       2       -       2  
Restricted stock units (RSUs)     28       54       28       54  
Warrants     1,405       1,420       1,405       1,420  
      2,311       1,870       2,311       1,870